2-((1S,2S,5S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)acetic acid → N-(3-tert-butylpyrazolo[1,5-a]pyrimidin-2-yl)-2-[(1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]acetamide
反応式
[C:1]([C:5]1[C:6]([NH2:14])=[N:7][N:8]2[CH:13]=[CH:12][CH:11]=[N:10][C:9]=12)([CH3:4])([CH3:3])[CH3:2].[CH3:15][C:16]1([CH3:27])[C@H:21]2[CH2:22][C@@H:17]1[CH2:18][CH2:19][C@H:20]2[CH2:23][C:24](O)=[O:25]>>[C:1]([C:5]1[C:6]([NH:14][C:24](=[O:25])[CH2:23][C@@H:20]2[CH2:19][CH2:18][C@H:17]3[CH2:22][C@@H:21]2[C:16]3([CH3:15])[CH3:27])=[N:7][N:8]2[CH:13]=[CH:12][CH:11]=[N:10][C:9]=12)([CH3:4])([CH3:2])[CH3:3]参加物
3
実験手順
The product from Example 105B and the product from Example 4B were processed using the method analogous to that described in Example 137 to afford the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.65-9.70 (bs, 1H), 8.92 (dd, J=6.3, 1.8 Hz, 1H), 8.48 (dd, J=4.1, 1.8 Hz, 1H), 6.99 (dd, J=6.7, 3.9 Hz, 1H), 2.52-2.59 (m, 1H), 2.25-2.47 (m, 3H), 1.78-2.00 (m, 5H), 1.48-1.52 (m, 1H), 1.45 (s, 9H), 1.15-1.21 (bs, 3H), 1.02-1.11 (bs, 3H), 0.91 (d, J=9.3 Hz, 1H); MS (DCI) m/z 355 (M+H)+.
出典と根拠
- ORDレコード
- ord-e85957fc3b6f44fea718d893363f94c6
- 出典データセット
- uspto-grants-2013_12
- 特許番号
- US08609669B2
反応ノート
読み込み中…